Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients

作者：Attallah Abdelfattah M^*; Omran Mohamed M; Farid Khaled; El Bendary Mahmoud; Emran Tarek M; Albannan Mohamed S; El Dosoky Ibrahim

来源：Clinica Chimica Acta, 2012, 413(21-22): 1725-1730.

DOI：10.1016/j.cca.2012.06.031

• HCV
• Liver fibrosis
• Blood markers
• Score

Background: This study aimed to develop and evaluate a predictive score named Fibrosis Routine Test (FRT) for liver fibrosis staging and to compare FRT with APRI, Lok, GUCI, FI, FibroQ FCI, FIB-4 and 4RLB scores in large numbers of untreated HCV-monoinfected patients. %26lt;br%26gt;Methods: Large numbers of estimation (N = 2045) and validation patients (N = 3212) were included in this study. Stepwise linear discriminant analysis and area under receiver-operating characteristic curves (AUCs) were used to create a predictive score comprising age, AFP. APRI and albumin. %26lt;br%26gt;Results: In the estimation study, FRT produced AUCs 0.84, 0.85 and 0.86 for significant (F2-F4), advanced fibrosis (F3-F4) and cirrhosis (F4), respectively. FRT %26gt; 4 was 83% specific and 73% sensitive for F2-F4, FRT %26gt; 5 was 83% specific and 71% sensitive for F3-F4 and FRT %26gt; 5.5 was 81% specific and 73% sensitive for F4. In the validation study, FRT produced AUCs 0.81, 0.89 and 0.95 for F2-F4, F3-F4 and F4, respectively. The above eight scores demonstrated lower AUCs than FRT. %26lt;br%26gt;Conclusion: While liver biopsy is invasive, costly and associated with complications, Fibrosis Routine Test (FRT) is a non-invasive, inexpensive, simple and may reduce the need of liver biopsy.

• 出版日期2012-11-12